Avicanna Inc. (AVCN.TO)
| Previous close | 0.3800 |
| Open | 0.3800 |
| Bid | 0.3650 x N/A |
| Ask | 0.3700 x N/A |
| Day's range | 0.3650 - 0.3800 |
| 52-week range | 0.2300 - 0.6000 |
| Volume | |
| Avg. volume | 119,062 |
| Market cap | 36.113M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings date | 13 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAvicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™ in Colombia by INVIMA for Patients with LGS and DS in Colombia. TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived ca
- GlobeNewswire
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of the
- GlobeNewswire
Avicanna Announces Closing of Non-brokered Private Placement
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 5,313,959 units of the Company (the “Units”) at a price of $0.40 per Unit for aggregate gross proceeds of approximately of $2,125,000. “We are very
